BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24018901)

  • 1. Hippuristanol reduces the viability of primary effusion lymphoma cells both in vitro and in vivo.
    Ishikawa C; Tanaka J; Katano H; Senba M; Mori N
    Mar Drugs; 2013 Sep; 11(9):3410-24. PubMed ID: 24018901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo anti-primary effusion lymphoma activities of fucoidan extracted from Cladosiphon okamuranus Tokida.
    Ishikawa C; Mori N
    Oncol Rep; 2017 Nov; 38(5):3197-3204. PubMed ID: 29048633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.
    Ueno M; Kariya R; Sittithumcharee G; Okada S
    Phytomedicine; 2021 May; 85():153545. PubMed ID: 33799222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-malaria agent artesunate exhibits cytotoxic effects in primary effusion lymphoma.
    Ishikawa C; Mori N
    Invest New Drugs; 2021 Feb; 39(1):111-121. PubMed ID: 32885355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells.
    Long C; Guo W; Zhou H; Wang J; Wang H; Sun X
    Int J Oncol; 2016 Apr; 48(4):1519-30. PubMed ID: 26821279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia.
    Tsumuraya T; Ishikawa C; Machijima Y; Nakachi S; Senba M; Tanaka J; Mori N
    Biochem Pharmacol; 2011 Mar; 81(6):713-22. PubMed ID: 21219881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways.
    Granato M; Rizzello C; Gilardini Montani MS; Cuomo L; Vitillo M; Santarelli R; Gonnella R; D'Orazi G; Faggioni A; Cirone M
    J Nutr Biochem; 2017 Mar; 41():124-136. PubMed ID: 28092744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression Ratios of the Antiapoptotic BCL2 Family Members Dictate the Selective Addiction of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Primary Effusion Lymphoma Cell Lines to MCL1.
    Dunham D; Viswanathan P; Gill J; Manzano M
    J Virol; 2022 Dec; 96(23):e0136022. PubMed ID: 36416587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
    Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
    mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulforaphane Exhibits Cytotoxic Effects against Primary Effusion Lymphoma Cells by Suppressing p38MAPK and AKT Phosphorylation.
    Ishiura Y; Ishimaru H; Watanabe T; Fujimuro M
    Biol Pharm Bull; 2019; 42(12):2109-2112. PubMed ID: 31787726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sangivamycin induces apoptosis by suppressing Erk signaling in primary effusion lymphoma cells.
    Wakao K; Watanabe T; Takadama T; Ui S; Shigemi Z; Kagawa H; Higashi C; Ohga R; Taira T; Fujimuro M
    Biochem Biophys Res Commun; 2014 Feb; 444(2):135-40. PubMed ID: 24434142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma.
    Kojima Y; Hayakawa F; Morishita T; Sugimoto K; Minamikawa Y; Iwase M; Yamamoto H; Hirano D; Imoto N; Shimada K; Okada S; Kiyoi H
    Pharmacol Res; 2017 Jun; 120():242-251. PubMed ID: 28396094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis.
    Hussain AR; Ahmed SO; Ahmed M; Khan OS; Al Abdulmohsen S; Platanias LC; Al-Kuraya KS; Uddin S
    PLoS One; 2012; 7(6):e39945. PubMed ID: 22768179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Butein inhibits NF-κB, AP-1 and Akt activation in adult T-cell leukemia/lymphoma.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2017 Aug; 51(2):633-643. PubMed ID: 28586006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
    Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
    mBio; 2018 May; 9(3):. PubMed ID: 29739902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7.
    Kim YJ; Kim Y; Kumar A; Kim CW; Toth Z; Cho NH; Lee HR
    PLoS Pathog; 2021 Jan; 17(1):e1009179. PubMed ID: 33471866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrrolidinium fullerene induces apoptosis by activation of procaspase-9 via suppression of Akt in primary effusion lymphoma.
    Watanabe T; Nakamura S; Ono T; Ui S; Yagi S; Kagawa H; Watanabe H; Ohe T; Mashino T; Fujimuro M
    Biochem Biophys Res Commun; 2014 Aug; 451(1):93-100. PubMed ID: 25063029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diallyl trisulfide induces apoptosis by suppressing NF-κB signaling through destabilization of TRAF6 in primary effusion lymphoma.
    Shigemi Z; Furukawa Y; Hosokawa K; Minami S; Matsuhiro J; Nakata S; Watanabe T; Kagawa H; Nakagawa K; Takeda H; Fujimuro M
    Int J Oncol; 2016 Jan; 48(1):293-304. PubMed ID: 26647777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.